Agenda 2024

DRAFT PROGRAMME  

Collaborating across the system and redesigning pharmacy services to optimise  

medicines value and improve outcomes 

https://medicinesforum.hsj.co.uk/  

08.00  

Registration & refreshments  

08.50  

Chair’s opening remarks  
Alastair McLellan, Editor, HSJ  

09.00  

KEYNOTE: The National Picture for Medicines and Pharmacy 

With significant changes to the medicine and pharmacy landscape we hear from senior national leadership on key strategic priorities and the landscape, such as: 

• Future of pharmacy services and the role of community pharmacy teams and independent prescribing in an integrated care environment of?  

• The importance of patient-centred care and tailored medication management strategies to optimise health outcomes. 

• How can effective collaboration between trusts, community pharmacy and ICS level regional strategy can effectively drive medicines optimisation 

• The anticipated challenges such as rising healthcare costs and the need for innovation and collaboration to address them effectively. 

• The strategic priorities for pharmacy practice, including expanding pharmacist roles in primary care and leveraging technology for enhanced patient outcomes. 

• How are we developing digital transformation for pharmacy services? 

09.45  

PANEL: How do pharmacies play a crucial part in reducing variation and health inequalities? 

• What is our main focus for improving prescribing? 

• How can we improve efficiency and personalisation of medicines? 

• How are ICBs monitoring Health Inequalities and how addressing them? 

• How do we reduce unwarranted variation, fairer equity to access of medicines and improve patients experience? 

• How do we collaborate and foster engagement from relevant stakeholders  

• What would it take to have a national formulary to aid the reduction of health inequalities? 

10.30 

Morning refreshments & networking  

11:00 

PANEL: Maximising value and outcomes through formulary reviews 

• Ensuring a holistic view of patient and population needs when creating evidence bases for first- and second-line prescribing decision making 

• Finding ways to balance costs, outcome measures and patient experience to ensure the greatest patient benefit is gained each time 

• Discussing why and how industry could facilitate better data sharing and evidence bases to inform decision making 

• Continuously assessing the impact of formulary changes on prescribing patterns to maximise value 

11:40 

PANEL: Optimising outcomes through service digitization and interoperability 

• What is the future of e-prescribing, including system-level implementation and legislative considerations? 

•  The importance of shared electronic health records for coordinated care delivery and patient safety. 

• How is the role of technology in enhancing decision-making processes and prioritising healthcare resources? 

• Address the need for universal access to digital healthcare systems, strategies for breaking down silos, and leveraging AI for improved patient care and outcomes. 

12:20 

Innovation Showcase 

1. AI and the impact on medicines 

2. Partner innovation Showcase 

3. Partner Innovation Showcase 

12.50 

Networking lunch  

13:40 

Interactive Workshops  
45 min interactive workshop sessions, with three running concurrently   

15:10  

Afternoon refreshments & networking   

15:40 

PANEL: Pharmacy First: 6 Months in: How is it working so far? 

• The framework for future commissioning of NHS Community Pharmacy 

• How is Pharmacy First working so far in the community with a significant increased footfall into community pharmacy?​ 

• Are we seeing the benefits in relieving pressures on GPs and primary care?  

• How are we managing work force and training for independent prescribing  

• Are there any teething problems in its implementation? 

• How is this working with the ICS? 

16:20  

PANEL: How are we managing devolved responsibility for specialised commissioning? 

• Case studies how services have been redesigned following delegation?   

• How working with neighbouring ICS? 

• How to manage the rising costs of medications within the context of specialised commissioning 

• Strategies for prioritizing and allocating resources effectively 

• How are we ensuring equitable access to specialised medications across different regions and patient populations can be challenging due to variations in funding, clinical criteria, and availability of treatments? 

• Considerations for balancing the need for innovative treatments with budget constraints 

17:20  

Chair’s closing remarks